Toni Choueiri
托尼·乔伊里
MD
Director, Lank Center for Genitourinary Oncology泌尿生殖肿瘤兰克中心主任
👥Biography 个人简介
Toni Choueiri is one of the world's most influential kidney cancer researchers, leading pivotal trials of nivolumab plus ipilimumab and IO/VEGF combinations at Dana-Farber. His work has established new first-line standards for metastatic RCC and advanced biomarker-driven patient selection.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
IO Combinations in First-Line RCC
Led CheckMate 214 and KEYNOTE-426 analyses establishing nivolumab+ipilimumab and pembrolizumab+axitinib as first-line standards, fundamentally changing metastatic RCC treatment.
VEGF/IO Combination Strategies
Pioneered and led pivotal trials of IO-VEGF combinations including pembrolizumab plus lenvatinib (CLEAR trial), defining new benchmarks for progression-free survival in mRCC.
Representative Works 代表性著作
Nivolumab plus Ipilimumab versus Sunitinib in First-Line Renal Cell Carcinoma
New England Journal of Medicine (2018)
CheckMate 214 establishing dual IO therapy superiority in intermediate/poor-risk metastatic RCC.
Lenvatinib plus Pembrolizumab versus Sunitinib in First-Line Renal Cell Carcinoma
New England Journal of Medicine (2021)
CLEAR trial demonstrating superior PFS and OS with lenvatinib/pembrolizumab versus sunitinib monotherapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Brian I. Rini
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Robert J. Motzer
Memorial Sloan Kettering Cancer Center
Toni K. Choueiri
Dana-Farber Cancer Institute, Harvard Medical School
Jonathan Rosenberg
Memorial Sloan Kettering Cancer Center
关注 托尼·乔伊里 的研究动态
Follow Toni Choueiri's research updates
留下邮箱，当我们发布与 Toni Choueiri（Dana-Farber Cancer Institute, Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment